 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 1234» |
- ||| Tybost (cobicistat) / Gilead, Tegsedi (inotersen) / Ionis, SOBI, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Journal, Adverse events: Drug-Associated Acute Kidney Disease: Data From a World Pharmacovigilance Database. (Pubmed Central) - Aug 2, 2024
We also highlight the potential nephrotoxic role of less suspected medications. This study emphasizes the need to consider AKD as a condition potentially associated with iatrogenic etiology, highlighting various medications and their respective involvement in the various possible manifestations of AKD.
- Unmissed cases of neurosyphilis: diagnosed by ophthalmologic examination (B / 01) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_5133;
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Journal: Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study. (Pubmed Central) - Jan 4, 2023
In our cohort, switching well-suppressed patients to E/C/F/TDF resulted in few virologic failures and was well tolerated. However, resistance to integrase inhibitors emerged in patients with virological failure.
- ||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Clinical, Review: I’ve always started w/ a 3 drug regimen, and my pts have been so heavily marketed to for the best “new” regimen (biktarvy is the new stribild). That said, this nice review has made me reconsider starting w/ 2 drug regimen 👇 https://t.co/DAAEv8NRCn (Twitter) - Dec 17, 2022
- ||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Clinical: I will say, my go-to first-line regimen is almost always tdf/ftc+dtg. I always discuss b/f/taf but i am not concerned about tdf renal tox unless i do concurrent cobi (eg stribild). Our patients are in their 20s/30s mainly.. so bmd less of a concern right now. (Twitter) - Dec 17, 2022
- | Vemlidy (tenofovir alafenamide) / Gilead
Journal: Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide. (Pubmed Central) - Nov 19, 2022
This strategy encouraged patients switching from Truvada to Descovy before the availability of generic Truvada. Conversely, Gilead offered lower discounts for Odefsey and Genvoya, which resulted into higher net prices compared to Complera and Stribild.
- || Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed, Trial primary completion date: Bictegravir in the Elderly Living With HIV (BICEP) (clinicaltrials.gov) - Nov 1, 2022
P=N/A, N=162, Active, not recruiting, Sponsor: State University of New York at Buffalo
Conversely, Gilead offered lower discounts for Odefsey and Genvoya, which resulted into higher net prices compared to Complera and Stribild. Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2022 --> Jul 2023
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion date: Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection (clinicaltrials.gov) - Oct 26, 2022
P=N/A, N=72, Active, not recruiting, Sponsor: University of California, Los Angeles
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2022 --> Jul 2023 Trial completion date: Jun 2022 --> Nov 2022
- ||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Only 28 HIV positive individuals on a Stribild regimen contracted SARS-Cov-2. (Twitter) - Oct 6, 2022
- || Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
INSTI-STRs used in Europe & Australia: is/was there anything other than Stribild® (predecessor of Genvoya®) ? (Twitter) - Jun 10, 2022
- || Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Correction: Except for Stribild there are no INSTI-STRs that contain TDF (Twitter) - Jun 10, 2022
- || Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
I agree that TAF (or better: switching off TDF) maybe key here… except for Stribild there are no STRs that contain TDF. There is data from the Swiss HUV cohort study to confirm the negative effects of this switch…and our VA data point in the same direction (Twitter) - Jun 10, 2022
- || Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
https://t.co/ZpOip6YacO #stribild @AssociatedPress @GileadSciences (Twitter) - Apr 8, 2022
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Journal, Real-world evidence: Effectiveness and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet combination among HIV-infected patients in Turkey: results from a real world setting. (Pubmed Central) - Mar 15, 2022
Adverse events were observed in 15% of the patients, and the regimen was discontinued in only six patients. Real world data on the effectiveness and safety of E/C/F/TDF is comparable with the phase 3 trial results Adverse events are uncommon and manageable.
- ||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Clinical, HEOR: For ART, we can debate whether TDF is risky or not, but there's just not an STR I use with TDF in my mostly ryan white clinic. If the patient is not feeling the higher cost of TAF regimen, I find it hard to fathom Rx-ing multiple pills or Stribild to "reduce healthcare costs" (Twitter) - Mar 3, 2022
- |||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
@GileadSciences @US_FDA @CDCgov #Stribild #toothloss #boneloss @MikeBloomberg @JohnsHopkinsSPH @BidenCancer @kathyireland @UNAIDS @ACLU @HRC @HRC_President @AlphonsoDavid @AssociatedPress @AP (Twitter) - Feb 24, 2022
- | Vitekta (elvitegravir) / Japan Tobacco, Gilead
Journal: Single-tablet regimen of emtricitabine/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims. (Pubmed Central) - Dec 16, 2021
Real world data on the effectiveness and safety of E/C/F/TDF is comparable with the phase 3 trial results Adverse events are uncommon and manageable. Sexual assault victims who were prescribed an STR based on EVG/COBI/FTC/TDF were more likely to complete PEP than those who were prescribed an MTR.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J, Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) / J&J, Gilead
Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) and rilpivirine/emtricitabine/tenofovir alafenamide (R/F/TAF) in treatment-naïve and treatment-experienced people living with HIV (PLWH) - 24-month results of the French TARANIS cohort (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_546;
Discontinuations were mainly attributed to non-treatment-related reasons. Emergence of resistance was rare (100,000 cp/mL, n (%) HIV-1-RNA 5%, n (%)hypertension: 52 (16.0)hyperlipidemia: 39 (12.0)neuropsychiatric disorder: 38 (11.7)cardiovascular: 21 (6.5)chronic hepatitis C: 20 (6.2)diabetes mellitus: 18 (5.5)hypertension: 4 (5.7)hyperlipidemia: 2 (2.9)neuropsychiatric disorder: 3 (4.3)cardiovascular: 3 (4.3)chronic hepatitis C: 1 (1.4)diabetes mellitus: 2 (2.9)hypertension: 48 (18.8)hyperlipidemia: 37 (14.5)neuropsychiatric disorder: 35 (13.7)cardiovascular: 18 (7.1)chronic hepatitis C: 19 (7.5)diabetes mellitus: 16 (6.3)Any baseline resistance associated mutation (RAM), n (%) Any NRTI RAM, n (%)* Any major INSTI RAM, n (%) No resistance data, n (%)149 (45.8)45 (13.8)0 (0)123 (37.8)34 (48.6)8 (11.4)0 (0)17 (24.3)115 (45.1)37 (14.5)0 (0)106 (41.6)TDF-based ART prior to E/C/F/TAF----N/A220 (86.3)Components/drug classes used in previous ART**, n (%) INSTI NNRTI PI information missing----N/A146 (57.3); [E/C/F/TDF: 103 (40.4)]49 (19.2)61 (23.9)3 (1.2)IQR, inter quartile range; N/A, not applicable; *most common M184V/I (n=16), D67N (n=10), K219Q/E/N/R (n=10); **overlap possibleTable 2. Baseline characteristics of the R/F/TAF analysis population for TE patientsTE (n=313, 100%)Male gender, n (%)236 (75.4)Age, years, median (IQR)50 (41-56)Time since diagnosis, years (IQR)12.0 (6.5-21.0)CDC stage C, n (%)44 (14.1)CD4 count, cells/µl, median (IQR)689 (497-879)HIV-1-RNA 5%, n (%) hypertension: 48 (15.3) hyperlipidemia: 43 (13.7) neuropsychiatric disorders: 42 (13.4) chronic hepatitis C: 26 (8.3) osteopathic disorders: 24 (7.7) cardiovascular: 21 (6.7) diabetes mellitus: 18 (5.8)Any baseline resistance associated mutation (RAM), n (%) Any NRTI RAM, n (%)* Any major INSTI RAM, n (%) No resistance data, n (%)131 (41.9)29* (9.3)8** (2.6)127 (40.6)TDF-based ART prior to E/C/F/TAF288 (92.0)Components/drug classes used in previous ART**, n (%) INSTI NNRTI PI 16 (5.1)272 (86.9); [R/F/TDF: 214 (68.4)]19 (6.1)IQR: inter quartile range; *most common M41L (n=12), T215Y/F (n=12), M184V/I (n=9); **E138K (n=1), G190A/S/E (n=2), K101E/P (n=1), K103N/S (n=3), Y181C/I/V (n=1); ***overlap of groups possible
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J, Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) / J&J, Gilead
Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) and rilpivirine/emtricitabine/tenofovir alafenamide (R/F/TAF) in treatment-naïve and treatment-experienced people living with HIV (PLWH) - 24-month results of the French TARANIS cohort (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_79;
Discontinuations were mainly attributed to non-treatment-related reasons. Emergence of resistance was rare (100,000 cp/mL, n (%) HIV-1-RNA 5%, n (%)hypertension: 52 (16.0)hyperlipidemia: 39 (12.0)neuropsychiatric disorder: 38 (11.7)cardiovascular: 21 (6.5)chronic hepatitis C: 20 (6.2)diabetes mellitus: 18 (5.5)hypertension: 4 (5.7)hyperlipidemia: 2 (2.9)neuropsychiatric disorder: 3 (4.3)cardiovascular: 3 (4.3)chronic hepatitis C: 1 (1.4)diabetes mellitus: 2 (2.9)hypertension: 48 (18.8)hyperlipidemia: 37 (14.5)neuropsychiatric disorder: 35 (13.7)cardiovascular: 18 (7.1)chronic hepatitis C: 19 (7.5)diabetes mellitus: 16 (6.3)Any baseline resistance associated mutation (RAM), n (%) Any NRTI RAM, n (%)* Any major INSTI RAM, n (%) No resistance data, n (%)149 (45.8)45 (13.8)0 (0)123 (37.8)34 (48.6)8 (11.4)0 (0)17 (24.3)115 (45.1)37 (14.5)0 (0)106 (41.6)TDF-based ART prior to E/C/F/TAF----N/A220 (86.3)Components/drug classes used in previous ART**, n (%) INSTI NNRTI PI information missing----N/A146 (57.3); [E/C/F/TDF: 103 (40.4)]49 (19.2)61 (23.9)3 (1.2)IQR, inter quartile range; N/A, not applicable; *most common M184V/I (n=16), D67N (n=10), K219Q/E/N/R (n=10); **overlap possibleTable 2. Baseline characteristics of the R/F/TAF analysis population for TE patientsTE (n=313, 100%)Male gender, n (%)236 (75.4)Age, years, median (IQR)50 (41-56)Time since diagnosis, years (IQR)12.0 (6.5-21.0)CDC stage C, n (%)44 (14.1)CD4 count, cells/µl, median (IQR)689 (497-879)HIV-1-RNA 5%, n (%) hypertension: 48 (15.3) hyperlipidemia: 43 (13.7) neuropsychiatric disorders: 42 (13.4) chronic hepatitis C: 26 (8.3) osteopathic disorders: 24 (7.7) cardiovascular: 21 (6.7) diabetes mellitus: 18 (5.8)Any baseline resistance associated mutation (RAM), n (%) Any NRTI RAM, n (%)* Any major INSTI RAM, n (%) No resistance data, n (%)131 (41.9)29* (9.3)8** (2.6)127 (40.6)TDF-based ART prior to E/C/F/TAF288 (92.0)Components/drug classes used in previous ART**, n (%) INSTI NNRTI PI 16 (5.1)272 (86.9); [R/F/TDF: 214 (68.4)]19 (6.1)IQR: inter quartile range; *most common M41L (n=12), T215Y/F (n=12), M184V/I (n=9); **E138K (n=1), G190A/S/E (n=2), K101E/P (n=1), K103N/S (n=3), Y181C/I/V (n=1); ***overlap of groups possible
- || Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
FDA event: $GILD#Stribild #FDA approval @AndyBiotech @BertrandBio @megtirrell - #Biktarvy (Twitter) - Sep 10, 2021
- | Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed: ALTAR: Reducing Antiretroviral Treatments (clinicaltrials.gov) - Aug 9, 2021
P3, N=360, Active, not recruiting, Sponsor: ANRS, Emerging Infectious Diseases
Emergence of resistance was rare (100,000 cp/mL, n (%) HIV-1-RNA 5%, n (%)hypertension: 52 (16.0)hyperlipidemia: 39 (12.0)neuropsychiatric disorder: 38 (11.7)cardiovascular: 21 (6.5)chronic hepatitis C: 20 (6.2)diabetes mellitus: 18 (5.5)hypertension: 4 (5.7)hyperlipidemia: 2 (2.9)neuropsychiatric disorder: 3 (4.3)cardiovascular: 3 (4.3)chronic hepatitis C: 1 (1.4)diabetes mellitus: 2 (2.9)hypertension: 48 (18.8)hyperlipidemia: 37 (14.5)neuropsychiatric disorder: 35 (13.7)cardiovascular: 18 (7.1)chronic hepatitis C: 19 (7.5)diabetes mellitus: 16 (6.3)Any baseline resistance associated mutation (RAM), n (%) Any NRTI RAM, n (%)* Any major INSTI RAM, n (%) No resistance data, n (%)149 (45.8)45 (13.8)0 (0)123 (37.8)34 (48.6)8 (11.4)0 (0)17 (24.3)115 (45.1)37 (14.5)0 (0)106 (41.6)TDF-based ART prior to E/C/F/TAF----N/A220 (86.3)Components/drug classes used in previous ART**, n (%) INSTI NNRTI PI information missing----N/A146 (57.3); [E/C/F/TDF: 103 (40.4)]49 (19.2)61 (23.9)3 (1.2)IQR, inter quartile range; N/A, not applicable; *most common M184V/I (n=16), D67N (n=10), K219Q/E/N/R (n=10); **overlap possibleTable 2. Baseline characteristics of the R/F/TAF analysis population for TE patientsTE (n=313, 100%)Male gender, n (%)236 (75.4)Age, years, median (IQR)50 (41-56)Time since diagnosis, years (IQR)12.0 (6.5-21.0)CDC stage C, n (%)44 (14.1)CD4 count, cells/µl, median (IQR)689 (497-879)HIV-1-RNA 5%, n (%) hypertension: 48 (15.3) hyperlipidemia: 43 (13.7) neuropsychiatric disorders: 42 (13.4) chronic hepatitis C: 26 (8.3) osteopathic disorders: 24 (7.7) cardiovascular: 21 (6.7) diabetes mellitus: 18 (5.8)Any baseline resistance associated mutation (RAM), n (%) Any NRTI RAM, n (%)* Any major INSTI RAM, n (%) No resistance data, n (%)131 (41.9)29* (9.3)8** (2.6)127 (40.6)TDF-based ART prior to E/C/F/TAF288 (92.0)Components/drug classes used in previous ART**, n (%) INSTI NNRTI PI 16 (5.1)272 (86.9); [R/F/TDF: 214 (68.4)]19 (6.1)IQR: inter quartile range; *most common M41L (n=12), T215Y/F (n=12), M184V/I (n=9); **E138K (n=1), G190A/S/E (n=2), K101E/P (n=1), K103N/S (n=3), Y181C/I/V (n=1); ***overlap of groups possible Not yet recruiting --> Active, not recruiting
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion, Trial primary completion date: SABES: HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women (clinicaltrials.gov) - Jul 14, 2021
P4, N=223, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Mar 2019 --> Nov 2020
- |||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Clinical: 👏 Amazing! @The_BMC going live too. I remember being a @FenwayHealth resident and excitement starting my first patient on “the quad pill” when Stribild came out. Wild and so lucky the choices we have <10 years later! #HIV #TasP (Twitter) - Jun 11, 2021
- ritonavir / Generic mfg.
[VIRTUAL] Persistence of drug-drug interaction problems with contemporary antiretroviral therapy. The case of ergotism () - May 27, 2021 - Abstract #IASHIV2021IAS_HIV_1343;
BACKGROUND: Drug-drug interaction (DDI) potential of protease inhibitors (PI) based antiretroviral therapy (ART), especially if boosted by ritonavir, became a problem early on after its rollout, with increasing reports of harmful effects, resulting in a large and growing list of drugs and natural substances no to be used concomitantly. Adequate identification of ergotamine containing drugs, better counseling of patients and increased awareness in the health care personnel seem necessary to avoid its occurrence in a context of contemporary antiretroviral therapy.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
[VIRTUAL] Suppressive combination antiretroviral therapy in people infected with HIV-1 is associated with a decrease of the reactive dicarbonyl methylglyoxal. () - May 20, 2021 - Abstract #ECCMID2021ECCMID_3761;
Suppressive INSTI-STR is associated with a decrease of plasma concentration of MGO, sICAM-1 and sVCAM-1 . Since MGO is associated with age-related diseases, it is clinically relevant to further investigate MGO in (ageing) hiv infected patients.
- || Vemlidy (tenofovir alafenamide) / Gilead
PK/PD data, Journal: Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid. (Pubmed Central) - Apr 28, 2021
P=N/A
Switch to E/C/F/TAF was associated with reductions in TFV concentrations in CSF but stable EVG concentrations that exceeded the IC50 for wild-type HIV, suggesting that EVG achieves therapeutic concentrations in the central nervous system. No virologic failure or significant NC changes were detected following the switch.Clinical Trials Rwegistration: NCT02251236.
- | Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed, Trial completion date, Trial primary completion date: Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection (clinicaltrials.gov) - Mar 10, 2021
P=N/A, N=72, Active, not recruiting, Sponsor: University of California, Los Angeles
No virologic failure or significant NC changes were detected following the switch.Clinical Trials Rwegistration: NCT02251236. Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Feb 2020 --> Aug 2021
- || Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
When my love of makeup and HIV content collide 💊💋💄#hiv #hivpositive #gilead #stribild #uequalsu .@GileadSciences let’s collaborate and do a pallet! 💀 https://t.co/neW70oxDh7 (Twitter) - Feb 26, 2021
- || Clinical, Reimbursement, Journal, HEOR, Real-World Evidence, Medicaid: Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries. (Pubmed Central) - Jan 13, 2021
Among patients newly prescribed ART, STR initiators were significantly less likely to discontinue therapy and had greater adherence and persistence compared to MTR initiators. Regimens containing FTC/TAF as a backbone had higher persistence than those consisting of other backbones.
- Prezista (darunavir) / J&J
[VIRTUAL] Efficacy and durability of elvitegravir/cobicistat/emtricitabine/tenofovir plus darunavir in the treatment of resistant HIV: a multi-center chart review () - Dec 26, 2020 - Abstract #ASHP2020ASHP_2602;
Although there were many treatment failures, the primary causes of failure included nonadherence, advanced immunosuppression, and changes in therapy due to drug interactions. Further prospective research with a larger sample size must be conducted to evaluate the long-term effects of this therapeutic combination.
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Journal: Effects of Integrase Inhibitor-Based ART on the NLRP3 Inflammasome Among ART-Naïve People With HIV. (Pubmed Central) - Nov 3, 2020
P=N/A
Six months of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate significantly decreased caspase-1 levels in association with CD4+/CD8+ ratio recovery. Trial registration. ClinicalTrials.gov NCT01766726.
- [VIRTUAL] Evaluating the IMPACT on Pharmaceutical Expenditure of HIV in the USA between 2017-2020 () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1797;
Price rises in ARVs are, therefore, the majority driver of HIV pharmaceutical expenditure surges. This is also reflected in Medicaid expenditure increases, in which ARVs are consistently amongst the costliest drug classes.Unwarranted price increases may cause further patient access barriers and expand the population of HIV+ individuals who do not receive regular treatment.
- [VIRTUAL] Persistence of Guideline-Recommended Antiretroviral Therapy Regimens among Persons Living with HIV Newly Initiating Treatment in the US () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_1830;
Among US adult PLWH, STRs were associated with longer persistence on first-line therapy compared to MTRs. Among STRs, persistence was highest for BIC/FTC/TAF.
- ||||||| Tybost (cobicistat) / Gilead, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants (clinicaltrials.gov) - Apr 29, 2020
P3, N=1443, Completed, Sponsor: Gilead Sciences
Among STRs, persistence was highest for BIC/FTC/TAF. Active, not recruiting --> Completed
- || Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
هل دواء stribild ضمن ادوية الفاعليه ضد كوفيد ؟ (Twitter) - Apr 13, 2020
- | tenofovir disoproxil fumarate / Generic mfg., Vitekta (elvitegravir) / Japan Tobacco, Gilead
Journal: Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. (Pubmed Central) - Apr 1, 2020
It is unclear whether the small decrease in plasma NfL found after switch to TAF is of any clinical relevance, particularly with plasma NfL levels in both arms remaining within the limits found in HIV-negative controls. These results indicate that switching from TDF to TAF appears safe with regard to neuronal injury.
- ||| Tybost (cobicistat) / Gilead, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion date: Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants (clinicaltrials.gov) - Mar 27, 2020
P3, N=1443, Active, not recruiting, Sponsor: Gilead Sciences
These results indicate that switching from TDF to TAF appears safe with regard to neuronal injury. Trial completion date: Dec 2019 --> Apr 2020
- | Prezista (darunavir) / J&J
Observational data, Journal: Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen: Results from an Observational Cohort Study. (Pubmed Central) - Jan 29, 2020
Trial completion date: Dec 2019 --> Apr 2020 Our data show a favorable effect of EVG/c/FTC/TDF switch to preserve immune activation-driven damage to T cell homeostasis, restore the multifunctional properties of effector T cells, and possibly contain cell-associated HIV viral burden in already virologically suppressed patients.
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: SABES: HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women (clinicaltrials.gov) - Jan 15, 2020
P4, N=223, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Our data show a favorable effect of EVG/c/FTC/TDF switch to preserve immune activation-driven damage to T cell homeostasis, restore the multifunctional properties of effector T cells, and possibly contain cell-associated HIV viral burden in already virologically suppressed patients. Recruiting --> Active, not recruiting | N=150 --> 223 | Trial completion date: Aug 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Mar 2019
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Infections of the Kidney/Genitourinary Tract - Palmer (LACC 408 B) - Dec 3, 2019 - Abstract #USCAP2020USCAP_297;
He has a past medical history of HIV on Stribild (cobicistat, elvitegravir, emtricitabine, tenofovir)...Pertinent Laboratory Data: Vitals: Afebrile, BP 121/77, HR 62, RR 18 Lower extremities with 2+ edema bilateral, otherwise physical exam is unremarkable. BUN/Cr = 17/0.97 Albumin 1.7 UA +protein, negative blood, negative WBC Urine protein:creatinine ratio = 12.44 CD4 count 488 HIV VL undetected HAV, HBV, HCV negative
- || Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Stribild (Twitter) - Nov 23, 2019
- | Adempas (riociguat) / Bayer, University of Pittsburgh, lamivudine / Generic Mfg., abacavir / Generic Mfg.
Preclinical, Journal: In vitro-in vivo correlation of the drug-drug interaction potential of antiretroviral HIV treatment regimens on CYP1A1 substrate riociguat. (Pubmed Central) - Nov 23, 2019
Antiretroviral treatment containing the potent CYP1A1 inhibitor abacavir had the greatest impact on riociguat metabolic clearance. The impact of comedications containing only strong CYP3A4 inhibitors e.g. ritonavir was less pronounced, suggesting benefit of riociguat over PAH-targeting medications with contraindications for use with strong CYP3A4 inhibitors.
- || Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
El día de ayer vi a un paciente muy querido, que por cierto es "élite controller" y quiso tratarse. Le cambiaron de un esquema basado en atazanavir a stribild en el @Tu_IMSS y además le dijeron que hasta julio 2020 le darán biktarvy... (Twitter) - Nov 20, 2019
- || Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
El plan era que stribild dejara de ser el inhibidor de integrasa predominante y se usara más biktarvy dadas sus ventajas en varios sentidos. La transición en SS ya se hizo, por lo visto en el IMSS no aún y además hay desabasto! De acuerdo con Luis en su comentario del desabasto (Twitter) - Nov 20, 2019
- || Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) / Gilead, BMS, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Estimado doctor @CarlosdelRio7 dejemos el humor para otro momento. El desabasto intermintente de ARV en el @Tu_IMSS es estructural, ya de lustros. Por cierto, Stribild iba a ser el medicamento para sustituir Atripla. Una patente por otra. ¿Así estaba planeado? (Twitter) - Nov 20, 2019
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Effectiveness, persistence and safety in treatment-naïve and treatment-experienced HIV-1 infected patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) - 12-month evaluation of the French TARANIS cohort (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1632;
In the prospective French TARANIS cohort, persistence to E/C/F/TAF was high in TN and TE patients during the first year. Virologic effectiveness and safety of using E/C/F/TAF were confirmed in a real world setting with 7.4% discontinuations due to ADRs (not related to kidney or bone) and < 1% due to virologic failure.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Clinical experience of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in real life practice: data from the Turkish HIV-TR cohort (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1630;
In TE patients who switched from tenofovir disoproxil fumarate (TDF) to TAF, fasting lipid values increased compared to baseline while total/HDL cholesterol ratio did not change significantly. E/C/F/TAF had a high virological efficacy in both TN and TE patients and was tolerated very well.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Effectiveness, persistence and safety in treatment-naïve and treatment-experienced HIV-1 infected patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) - 12-month evaluation of the French TARANIS cohort (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_822;
In the prospective French TARANIS cohort, persistence to E/C/F/TAF was high in TN and TE patients during the first year. Virologic effectiveness and safety of using E/C/F/TAF were confirmed in a real world setting with 7.4% discontinuations due to ADRs (not related to kidney or bone) and < 1% due to virologic failure.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Clinical experience of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in real life practice: data from the Turkish HIV-TR cohort (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_820;
In TE patients who switched from tenofovir disoproxil fumarate (TDF) to TAF, fasting lipid values increased compared to baseline while total/HDL cholesterol ratio did not change significantly. E/C/F/TAF had a high virological efficacy in both TN and TE patients and was tolerated very well.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Effectiveness, persistence and safety in treatment-naïve and treatment-experienced HIV-1 infected patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) - 12-month evaluation of the French TARANIS cohort (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_74;
In the prospective French TARANIS cohort, persistence to E/C/F/TAF was high in TN and TE patients during the first year. Virologic effectiveness and safety of using E/C/F/TAF were confirmed in a real world setting with 7.4% discontinuations due to ADRs (not related to kidney or bone) and < 1% due to virologic failure.